enGenes Biotech to showcase enzyme production offers at Chemspec Europe

Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) will use the reconvened physical Chemspec Europe trade show in Frankfurt to highlight its advanced enzyme production platforms.

The reappearance of enGenes as a face-to-face presence at Chemspec maintains its long association with the event, that it attended virtually during the Covid pandemic.

Multichannel presence

The enGenes team in Frankfurt will be led by CEO, Dr. Jürgen Mairhofer, accompanied by Head of Business Development, Karl Hübler. Their physical presence at the event will be supported by an energetic enGenes presence on the Chemspec Digital Hub online platform, modelled on its successful similar virtual networking and presentation program at the recent BIO-Europe Digital event.

The team will be presenting enGenes industry-leading platforms for production of enzymes and recombinant proteins, spearheaded by its patented enGenes X-press® expression platform.

X-press advantages

“We’re very glad to be returning to a face to face physical Chemspec show,” said Dr. Mairhofer.

“We will be looking to network with industrial biotech companies in need of advanced and proven enzyme production platforms. where our X-press technology portfolio offers powerful advantages.”

“We can offer very cost-effective manufacturing solutions with our enGenes-X-press technology offering protein secretion allowing cost-effective downstream processing from E. coli cell free supernatants. We can also put partners in touch with our dedicated team of experts to discuss our innovative bioconjugation solution that can specifically modify recombinant proteins,” Dr. Mairhofer explained.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About Chemspec Europe 2022

The International Exhibition for Fine and Specialty Chemicals, Chemspec Europe, is the continent’s premier sourcing and networking event for manufacturers, suppliers and distributors of fine and specialty chemicals. Chemspec Europe is renowned for its specialized profile, presenting visitors and exhibitors with a platform to share knowledge about products and solutions.

The 35th Chemspec Europe expo (Chemspec 2022) is a two-day event opening May 31 at the Messe Exhibition Center in Frankfurt, Germany, reconfigured as a full physical event for the first time since 2019, having moved online during the global coronavirus pandemic.

The previous physical Chemspec show, in Basel, Switzerland (Chemspec 2019), attracted more than 400 exhibitors from 29 countries and some 7,000 attendees from all over the world.

The event is organized by Mack-Brooks Exhibitions with further information at https://www.chemspeceurope.com


Click on enGenes Biotech recombinant protein production for more information.

Die inhaltliche Verantwortung für diesen Beitrag liegt ausschließlich beim Aussender. Beiträge können Vorhersagen enthalten, die auf Erwartungen an zukünftige Ereignisse beruhen, die zur Zeit der Erstellung des Beitrags in Aussicht standen. Bitte verlassen Sie sich nicht auf diese zukunftsgerichteten Aussagen.

Als Life Sciences Organisation mit Sitz in Wien möchten Sie, dass LISAvienna auf Ihre News und Events hinweist? Senden Sie uns einfach Ihre Beiträge an news(at)lisavienna.at.